Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus

References

• Lipsky PE. Systemic lupus erythematosus: an autoimmune dis-ease of B cell hyperactivity. Nat Immunol. 2001;2:764–6.
   PubMed Web of Science ®Google Scholar
• Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 2006;24:467–96.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immu-nol. 2006;176(2):705–10.
   PubMed Web of Science ®Google Scholar
• Anderton SM, Fillatreau S. Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol. 2008;4:657–66.
   PubMedGoogle Scholar
• Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484–92.
   PubMed Web of Science ®Google Scholar
• Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006;2:20–7.
   PubMedGoogle Scholar
• Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resis-tant proliferative lupus nephritis. Arthritis Rheum. 2007; 56:1263–72.
   Google Scholar
• Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakaya-mada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous sys-tem. Ann Rheum Dis. 2007;66: 470–5.
   Google Scholar
• Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Long term clinical and immuno-logical effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826–33.
   PubMed Web of Science ®Google Scholar
• George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927–35.
   PubMed Web of Science ®Google Scholar
• George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rit-uximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab Treatment of thrombotic thrombocytopenic purpura-hemolytic uremic syn-drome in therapy for immune-mediated disorders. J Clin Apher. 2006;21:49–56.
   Google Scholar
• Shah AA, Higgins JP, Chakravarty EF. Thrombotic microang-iopathic hemolytic anemia in a patient with SLE: diagnostic difficulties. Nat Clin Pract Rheumatol. 2007;3:6–357.
   Google Scholar
• Niewold TB, Alpert D, Scanzello CR, Paget SA. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol. 2006;33:1194–6.
   PubMed Web of Science ®Google Scholar
• Limal N, Cacoub P, Sene D, Guichard I, Piette JC. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus. 2008;17:69–71.
   Google Scholar
• Letchumanan P, Ng RI, Lee LH, Thumboo J. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheu-matology. 2009;48:399–403.
   PubMed Web of Science ®Google Scholar
• Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347:589–600.
   PubMed Web of Science ®Google Scholar
• Miyamura T, Watanabe H, Takahama S, Sonomoto K, Nakamura M, Ando H, et al. Thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi. 2008;31:159-65. Japanese.
   Google Scholar
• Lambotte 0, Khellaf M, Harmouche H, Bader-Meunier B, Manceron V, Goujard C, et al. Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-asso-ciated hemophagocytic syndrome. Medicine. 2006;85: 169–82.
   Google Scholar
• Kumakura S, Ishikura H, Kondo M, Murakawa Y, Masuda J, Kobayashi S. Autoimmune-associated hemophagocytic syn-drome. Mod Rheumatol. 2004;14:205–15.
   PubMedGoogle Scholar
• Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune dis-eases. Autoimmun Rev. 2007;6:457–63.
   PubMed Web of Science ®Google Scholar
• Bruns A, Bläss S, Hausdorf G, Burmester GR, Hiepe F. Nude-osomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum. 2000;43:2307–15.
   PubMedGoogle Scholar
• Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008;205:3007–18.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Yanab K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118:3420–30.
   Google Scholar
• Goetz M, Atrey R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13:1365–8.
   PubMed Web of Science ®Google Scholar
• Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56:2715–8.
   Google Scholar
• Kfoury Baz EM, Mikati AR, Kanj NA. Reactive hemophagocytic syndrome associated with thrombotic thrombocytopenic purpura during therapeutic plasma exchange. 'Ther Apher. 2002;6:159–62.
   Google Scholar
• Yamada T, Handa Y, Kamikawa T, Machino H, Suzuki K, Miyata K. A case of systemic lupus erythematosus associated with thrombotic thrombocytopenic purpura and hemophagocytic syndrome. Nihon Rinsho Meneki Gakkai Kaishi. 2006;29:384-8. Japanese.
   Google Scholar